

1 **Predicting the causal relationship between polyunsaturated fatty**
2 **acids and cerebral aneurysm risk from a**
3 **Mendelian randomization study**

4 **Authors**

5 Weijie Yu^{1,3†}, Yunyun Mei^{2†}, Chongfei Li^{1,3†}, Zhenwei Lu^{1,3}, Xiaoyu Chen⁴, Hao Yu⁴, Xiaoyan Chen⁵,
6 Qionghui Huang^{1,6}, Zhangyu Li³, Deyong Xiao³, Liwei Zhou^{3*}, Zhanxian Wang^{3*}

7 **Author Affiliations**

8 1 The School of Clinical Medicine, Fujian Medical University, Fuzhou 350122, China.

9 2 Department of Neurosurgery, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen
10 361026, China.

11 3 Department of Neurosurgery, Department of Neurosurgery Quality Control Center, The First
12 Affiliated Hospital of Xiamen University, Xiamen Key Laboratory of Brain Center, Xiamen 361003,
13 China.

14 4 School of Medicine, Xiamen University

15 5 Internal medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.

16 6 Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, Xiamen Key
17 Laboratory of Brain Center, Xiamen 361003, China.

18 **†Co-first author**

19 Weijie Yu, Yunyun Mei and Chongfei Li contributed equally as the first authors.

20 *** Corresponding Author**

21 Liwei Zhou, MS. Department of Neurosurgery, The First Affiliated Hospital of Xiamen University,
22 Xiamen Key Laboratory of Brain Center, 55 Zhenhai Road, Siming District, Xiamen City, Fujian,
23 361003, P.R. China (Email: 1769958372@qq.com).

24 Zhanxiang Wang, MD. Department of Neurosurgery, The First Affiliated Hospital of Xiamen

25 University, Xiamen Key Laboratory of Brain Center, 55 Zhenhai Road, Xiamen Siming District,

26 Xiamen City, Fujian, 361003, P.R. China (Email: zhanxiangW_sjwk@163.com).

27

28 **Abstract**

29 **Introduction:** No conclusive evidence for a link between polyunsaturated fatty acids (PUFA) and
30 cerebral aneurysm has been found in observational research. The aim of our study was to determine the
31 causal impact of PUFA on cerebral aneurysm.

32 **Methods:** Two sample Mendelian randomization (MR) was performed using genetic instruments
33 derived from a recent genome wide association study (GWAS) of fatty acids from UK Biobank and
34 outcome data obtained from the large-scale cerebral aneurysm GWASs in European ancestry which
35 include IA, aneurysmal subarachnoid hemorrhage (aSAH) and unruptured intracranial aneurysm (uIA).
36 Sensitivity analyses were implemented with MR-Egger intercept test, MR-PRESSO, leave-one-out
37 analysis and so on. Bayesian colocalization (COLOC) methods was conducted to focus on the
38 association between the fatty acid gene expression and cerebral aneurysm.

39 **Results:** Genetically predicted assessed omega-3 fatty acids decreased the risk for IA (OR = 0.80, 95%
40 CI: 0.69 - 0.91, $P = 1.01 \times 10^{-3}$) and aSAH (OR = 0.71, 95% CI: 0.61 - 0.84, $P = 3.73 \times 10^{-5}$). Furthermore,
41 the Docosahexaenoic acid decreased the risk for IA (OR = 0.75, 95% CI: 0.63 - 0.87, $P = 3.12 \times 10^{-4}$)
42 and aSAH (OR = 0.67, 95% CI: 0.55 - 0.8, $P = 2.32 \times 10^{-5}$). The same results were discovered from ratio
43 of omega-3 fatty acids to total fatty acids. While the ratio of omega-6 fatty acids to omega-3 fatty acids
44 increased the risk of IA (OR = 1.27, 95% CI: 1.12 – 1.44, $P = 1.53 \times 10^{-4}$) and aSAH (OR = 1.35, 95%
45 CI: 1.17 – 1.56, $P = 5.78 \times 10^{-5}$). The result of the COLOC suggested that the above four kinds of fatty
46 acids and IA, aSAH likely share causal variants in gene fatty acid desaturase 2, separately.

47 **Conclusion:** This study utilized integrative analysis of MR and colocalization to discover causal
48 relationships between genetic variants, PUFA and cerebral aneurysm.

49 **Funding:** This study was funded by the Natural Science Foundation of China (82072777), the Natural
50 Science Foundation of Xiamen (3502Z20227097), Fujian Provincial Health Commission, Provincial
51 Health and Health Young and Middle-aged Backbone Talent Training Project (2022GGB010).

52

53 **Keywords:** polyunsaturated fatty acids, intracranial aneurysm, subarachnoid hemorrhage, Mendelian
54 randomization.

55

56

57 **Introduction**

58 Intracranial aneurysm (IA) is confined, pathological dilatations of the walls of intracranial arteries,
59 which currently considered a chronic inflammatory disease that affects the intracranial arteries (Aoki et
60 al., 2017) with a prevalence of approximately 3% in the general population (Vlak et al., 2011). About
61 85% of spontaneous subarachnoid hemorrhage (SAH) is due to ruptured IA (Macdonald et al., 2017).
62 Unruptured IAs (uIAs) are frequently asymptomatic, but IA rupture can result in aneurysmal
63 subarachnoid hemorrhage (aSAH), which has a poor prognosis (30% of death, 30% of independence
64 and 30% of dependence), with patients often suffering from a disability or even death (Chen et al.,
65 2020; (Nieuwkamp et al., 2009). In light of the elevated rates of mortality and morbidity brought on
66 by IA, it is crucial to explore the pathogenesis of intracranial aneurysm.

67 Polyunsaturated fatty acids (PUFA) are fatty acids that contain multiple double bonds in their
68 molecular structure. According to the position and number of double bonds, polyunsaturated fatty acids
69 can be further divided into two categories, omega-3 and omega-6. The long-chain omega-3
70 polyunsaturated fatty acid (omega-3) and docosahexaenoic acid (DHA) have been suggested to have
71 cardioprotective (Burr et al., 1989; (Wang et al., 2006), anti-inflammatory (Massaro et al., 2006),
72 immunoregulatory (Yang et al., 2013), antioxidant (Carrepeiro et al., 2011; (Bouzidi et al., 2010) and
73 anti-tumor activities (Calviello et al., 2006). A recent study reported a significant decrease in red blood
74 cell distribution width, pulse wave analysis and heart rate in patients with abdominal aortic aneurysm
75 who were supplemented with 1.8 g of long-chain omega-3 polyunsaturated fatty acids for 12 weeks,
76 suggesting an improving in intravascular inflammation and vascular stiffness (Meital et al., 2019;
77 (Meital et al., 2020). Omega-3 and DHA down-regulate multiple aspects of the inflammatory process,
78 such as oxidative stress and inflammation in macrophages (Meital et al., 2019). According to a recent
79 retrospective study, high levels of free fatty acids on admission can provide some reference predictions
80 for the poor prognosis of patients with aSAH at 3 months (Wang et al., 2021). Other studies
81 demonstrated that arachidonic acid (AA) and AA-containing phospholipids were not detected in
82 unruptured IA walls, whereas AA and AA-containing phospholipids were detected in significantly
83 higher amounts in ruptured IA walls than in unruptured IA walls (Takeda et al., 2021).

84 Mendelian randomization (MR) is the use of genetic variation in non-experimental data to
85 estimate the causal link between exposure and outcome, and it can reduce the impact of behavioral,
86 social, psychological, and other factors (Davey Smith et al., 2014). And in recent years, many MR
87 studies have emerged to provide clinical evidence (Hu et al., 2023; (Yuan et al., 2019). To investigate
88 the etiology of cerebral aneurysms, it is essential to further clarification of the causal relationship
89 between PUFAs and cerebral aneurysms through Mendelian randomization.

90 **Methods**

91 **Study design**

92 In this study, we performed a two-sample Mendelian randomization analysis to examine the
93 causal effects of PUFA and cerebral aneurysms using genome wide association study (GWAS)
94 summary statistics. This instrumental-variable analysis mimics RCT with respect to the random
95 allocation of single nucleotide polymorphisms (SNPs) in offspring (independent of confounding factors
96 such as sex and age). In addition, this MR design has to fulfill three assumptions: (i) genetic

97 instruments predict the exposure of interest ($P < 5 \times 10^{-8}$); (ii) genetic instruments are independent of
98 potential confounders; (iii) genetic instruments affects the outcome only via the risk factors (Boef et al.,
99 2015). The MR analysis used summary GWAS data publicly available from GWASs and no individual
100 level data used. Due to the fact that each of the original GWASs had obtained ethical approval and
101 participant consent, they were not required.

102 **Data source and selection of genetic instruments**

103 SNPs associated with 5 PUFAs were obtained from the open GWAS website, containing omega-3
104 fatty acids, omega-6 fatty acids, DHA, the ratio of omega-3 fatty acids to total fatty acids and ratio of
105 omega-6 fatty acids to omega-3 fatty acids. According to the GWAS id, we named the ratio of omega-3
106 fatty acids to total fatty acids and ratio of omega-6 fatty acids to omega-3 fatty acids abbreviated as
107 omega-3-pct and omega-6 by omega-3, respectively. They are derived from a large-scale UK Biobank
108 GWAS of fatty acids with 114,999 individuals of European ancestry (Borges et al., 2022). Circulating
109 omega-3 (i.e., DHA and total omega-3) and omega-6 (i.e., linoleic acid and total omega-6) fatty acid
110 concentration were measured using a targeted high-throughput nuclear magnetic resonance
111 metabolomics platform (Julkunen et al., 2021). The mean concentration of total omega-3 fatty acids,
112 DHA and omega-6 fatty acids was 0.53 (SD 0.22) mmol/L, 0.23 (SD 0.08) mmol/L and 4.45 (SD 0.68)
113 mmol/L. (Supplementary Table 1)

114 For the outcome, the genetic effect of the corresponding SNP on IA and aSAH were obtained
115 from the most recent GWAS with a total of 65796 Europeans (6252 IA cases and 59544 controls) and
116 63740 Europeans (4196 aSAH cases and 59544 controls) after excluding UK Biobank (Bakker et al.,
117 2020). And Summary statistics for uIA phenotypes were extracted from the from the FinnGen database
118 (https://r8.finnngen.fi/pheno/I9_ANEURYSM) with a total of 314556 Europeans (1788 uIA cases and
119 312768 controls). (Supplementary Table 1)

120 According three essential model assumptions of MR. First, SNPs were associated with the
121 appropriate exposure at the genome-wide significance threshold $P < 5 \times 10^{-8}$. Second, to quantify the
122 strength of the genetic instruments, SNPs with an F statistic less than 10 were excluded. Third, we
123 clustered SNPs in linkage disequilibrium (LD, $R^2 \geq 0.001$ and within 10 mb). Fourth, to eliminate
124 unclear, palindromic and associated with known confounding factors (body mass index (McDowell et
125 al., 2018), blood pressure (Sun et al., 2022), type 2 diabetes (Tian et al., 2022), high-density lipoprotein
126 (Huang et al., 2018)) SNPs. Fifth, If an instrumental SNP for the exposure was not available from the
127 outcome data set, we replaced it with a suitable proxy SNP ($r^2 > 0.8$ in the European 1000 Genomes
128 Project reference panel using LDlink <https://ldlink.nci.nih.gov/>) or removed it in the absence of such a
129 proxy. SNPS located in the MHC region were removed. Finally, removing SNPs with potential
130 pleiotropy and outlier through mendelian randomization pleiotropy residual sum and outlier
131 (MR-PRESSO). Then, the heterogeneity between-SNP were tested using inverse variance weighting
132 (IVW) and the MR-Egger method based on the SNPs that were retained after pleiotropy correction.
133 (Figure 1.) Details of the SNPs used as instrumental variables were displayed in Supplementary Tables
134 2 - 4.

135 **Mendelian randomization analyses and Sensitivity analysis**

136 Eleven MR analytical approaches were used in this study to investigate the causal impacts of
137 PUFA on the cerebral aneurysm. As the main analysis, we used standard IVW estimates, is
138 characterized by an analysis that does not take into account the presence of an intercept term and uses
139 the inverse of the outcome variance (quadratic of the standard error) as a weight to provide a
140 comprehensive estimate of the impact of the PUFA on the cerebral aneurysm. Furthermore, additional
141 MR analyses, such as MR-Egger regression, weighted median, simple mode, weighted mode methods
142 and so on were implemented as complements to the IVW, because these methods could provide more
143 robust estimates over a wider range of scenarios. The MR-Egger method can provide causal estimates
144 that are unaffected by breaches of standard IV assumptions and can detect whether standard IV
145 assumptions are violated (Bowden et al., 2015). The weighted median method provides consistent
146 estimates of effect, when at least half of the weighted variance provided by horizontal pleiotropy is
147 valid (Bowden et al., 2016). We also performed reverse MR studies, where the cerebral aneurysms
148 were treated as the exposure and PUFA was treated as the result, in order to thoroughly investigate the
149 potential existence of reverse causation. To assess the robustness of the above results, a series of
150 sensitivity analyses, including IVW, MR-Egger, MR-Egger intercept test, MR-PRESSO global test and
151 “leave-one-out” method were conducted.

152 **Bayesian colocalization (COLOC)**

153 Bayesian colocalization (COLOC) analysis assesses whether single-nucleotide variants linked to
154 gene expression and phenotype at the same locus are shared causal variants, and thus, gene expression
155 and phenotype are “colocalized.” This approach assumes that: (1) in each test region, there exists at
156 most one causal SNP for either trait; (2) the probability that a SNP is causal is independent of the
157 probability that any other SNP in the genome is causal; (3) all causal SNPs are genotyped or imputed
158 and included in analysis. According to these assumptions, there are five mutually exclusive hypotheses
159 for each test region: (1) there is no causal SNP for either trait (H0); (2) there is one causal SNP for trait
160 1 only (H1); (3) there is one causal SNP for trait 2 only (H2); (4) there are two distinct causal SNPs,
161 one for each trait (H3); and (5) there is a causal SNP common to both traits (H4). A large PP for H4
162 (PP.H4 above 0.75) strongly supports shared causal variants affecting both gene expression and
163 phenotype (Kurki et al., 2023).

164 **Statistical Analysis**

165 For the MR analysis, IVs with F values over 10 were considered strong instruments that could
166 alleviate bias from weak instruments (Pierce et al., 2011). The formula used to calculate F values is as
167 follows: $F = [(N-K-1) R^2] / [k(1-R^2)]$, where R^2 represents the proportion of variance explained by the
168 genetic variants, N represents the sample size, and k represents the number of included SNPs. $R^2 =$
169 $\sum_1^k 2\beta^2(1 - EAF)EAF$, where EAF is the effect allele frequency and β is the estimated effect on LTL
170 (Park et al., 2010). Given the limited number of cases in the GWAS, we calculated the statistical power
171 for MR analysis using the mRnd website (<https://shiny.cnsgenomics.com/mRnd/>). To account for
172 multiple testing in our primary analyses, a Bonferroni-corrected threshold of $P < 0.0033$ ($\alpha=0.05/15$ [5
173 exposures and 3 outcomes]) was applied. All statistical analyses performed in this investigation were
174 carried out using the “TwoSampleMR”, “phenoscanner”, “RadialMR”, “MendelianRandomization”
175 and “MRPRESSO” packages in R software (version 4.2.2).

176 Results

177 According to the above methodology, we filtered out the corresponding SNPs. (Supplementary
178 Table 2 – 4)

179 In the outcome of IA, IVW analysis indicated that omega-3 fatty acid (OR = 0.80, 95% CI: 0.69
180 - 0.91, $P = 1.01 \times 10^{-3}$), DHA (OR = 0.75, 95% CI: 0.63 - 0.87, $P = 3.12 \times 10^{-4}$) and omega-3-pct (OR =
181 0.8, 95% CI: 0.71 - 0.90, $P = 2.34 \times 10^{-4}$) decreased the risk for IA. And omega-6 by omega-3 increased
182 the risk for IA (OR = 1.27, 95% CI: 1.12 – 1.44, $P = 1.53 \times 10^{-4}$). The results and directionality of other
183 MR methods revealed consistency. (Supplementary Figure 1) However, there was no any causal
184 relationship between Omega-6 fatty acid and IA. (Figure 2.)

185 In the outcome of aSAH, omega-3 fatty acid (OR = 0.71, 95% CI: 0.61 - 0.84, $P = 3.73 \times 10^{-5}$),
186 DHA (OR = 0.67, 95% CI: 0.55 - 0.80, $P = 2.32 \times 10^{-5}$) and omega-3-pct (OR = 0.76, 95% CI: 0.66 -
187 0.87, $P = 1.16 \times 10^{-4}$) decreased the risk for aSAH. And omega-6 by omega-3 increased the risk for
188 aSAH (OR = 1.35, 95% CI: 1.17 – 1.56, $P = 5.78 \times 10^{-5}$). The results and directionality of other MR
189 methods revealed consistency. (Supplementary Figure 2) However, there was no any causal
190 relationship between omega-6 fatty acid and aSAH. (Figure 3.)

191 In the outcome of uIA, there was no any causal relationship between all of the above five PUFAs
192 and uIA. (Figure 4.) In the result of reverse MR, MR analysis of all groups failed sterling filiting test.

193 To assess the robustness of the above results, a series of sensitivity analyses, including MR-Egger,
194 IVW, MR-Egger intercept test, “leave-one-out” method and MR-PRESSO global test, were conducted
195 (Supplementary Table 5 and Supplementary Figure 3-5). All P-values of the MR-Egger intercept tests,
196 Q test and MR-PRESSO were > 0.05 , indicating that no horizontal pleiotropy and heterogeneity existed.
197 All steiger test indicated correct directionality.

198 Although there is consistent evidence that PUFAs have a beneficial causal effect on cerebral
199 aneurysm, it is uncertain if PUFAs are mediators in the hereditary causative route of cerebral aneurysm.
200 For achieve that, we tested for shared causative SNPs between PUFAs and cerebral aneurysm using
201 COLOC. In COLOC analysis, we further calculated the posterior probability of each SNP being causal
202 to both of the traits (PPH4). We identified shared causal SNP of omega-3 fatty acid and IA, aSAH in
203 gene fatty acid desaturase 2 (*FADS2*), respectively. Similarly, in DHA, omega-3-pct, omega-6 by
204 omega-3, these three fatty acids and IA, aSAH also obtain the same result. (Table 1.)

205

206

207 Discussion

208 PUFA supplementation is controversial for the prevention of cerebral aneurysm disease, while
209 cerebral aneurysm is a heterogeneous disease with various pathogenic mechanisms. Here, we
210 implemented multiple rigorous MR methods to appraise the possible causal association of PUFA with
211 cerebral aneurysm and its different states. We demonstrated that the omega-3 fatty acids, DHA,
212 omega-3-pct, and omega-6 by omega-3 causally decreased the risk for IA and aSAH. And omega-6
213 fatty acids causally increased the risk of IA and aSAH. In addition to IVW, consistency was seen in the
214 outcomes and directionality of different MR methods. We identified shared causal SNPs of omega-3
215 fatty acid, DHA, omega-3-pct, omega-6 by omega-3 and IA in genes *FADS2*, respectively. The same
216 results were acquired from these four PUFAs and aSAH. The results of reverse MR and COLOC
217 jointly increase the validity of our findings.

218 This could be connected to PUFAs can decrease the aneurysm's inflammatory process. The
219 pathophysiology of IA involves inflammatory processes (Ge et al., 2022), which may include
220 degeneration of the endothelium and vasa vasorum, as well as fragmentation of the internal elastic
221 lamina (Nakatomi et al., 2000; (Meng et al., 2014). As an underlying mechanism, the prostaglandin
222 E2 in macrophages was considered by Aoki et al. as a factor regulating such chronic inflammation
223 involved in the progression and rupture of IAs (Aoki et al., 2017). However, multiple elements of the
224 inflammatory process, including oxidative stress and inflammation in macrophages, can be
225 downregulated by omega-3 and DHA (Meital et al., 2019). In the Abdominal aortic aneurysm (AAA),
226 supplementation with the omega-3 PUFA, DHA, suppressed production of 8-isoprostane, the gold
227 standard biomarker of oxidative stress and a specific marker of lipid peroxidation (Kadiiska et al.,
228 2005). The results concord with data from both experimental animal studies (Saraswathi et al., 2007;
229 (Zúñiga et al., 2010) and human clinical trials (Mori et al., 2003; (Barden et al., 2015) that suggest
230 omega-3 PUFAs decrease 8-isoprostane levels and ease oxidative stress. The findings from a
231 randomized controlled trial suggest that omega-3 PUFAs improve erythrocyte fatty acid profile and
232 ameliorate factors associated with inflammation in AAA patients (Meital et al., 2019). For aSAH, a
233 prospective study demonstrated that administration of omega-3 fatty acids after aneurysmal SAH may
234 reduce the frequency of cerebral vasospasm through the effects of anti-inflammatory and reduce both
235 platelet aggregation and plasma triglycerides, and have neuroprotective effects and may improve
236 clinical outcomes (Nakagawa et al., 2017). At the same time, it may have a preventive effect on the
237 complication of intracranial hemorrhage after aneurysm surgery (Saito et al., 2017). A multi-center
238 study with a sizable sample size is still required to clarify the trend of the effect of omega-3 fatty acids
239 on aSAH, even though the favorable outcomes of these two studies have a certain reference value.
240 Furthermore, Ririko et al. findings that AA and AA-containing phospholipids were not detected in the
241 unruptured IA while they were detected in a significantly larger amount in the ruptured IA and suggest
242 that the stability of the turnover of AA and linoleic acid in human unruptured IA walls is sustained
243 (Takeda et al., 2021). Several earlier studies employing rat model found that the thickened aneurysmal
244 wall and various brain areas after subarachnoid hemorrhage had higher amounts of free fatty acids,
245 including AA (Gewirtz et al., 1999; (Ikedo et al., 2018). This is in line with results of our MR
246 analyses between omega-6 fatty acid and aSAH.

247 Besides, in the development of cardiovascular disease, genetically higher plasma α -linolenic and
248 linoleic are inversely associated with large-artery stroke and venous thromboembolism, whereas AA
249 level have a favorable correlation with these cardiovascular diseases (Yuan et al., 2019). This is may be
250 associated with the $\Delta 5$ -desaturase and $\Delta 6$ -desaturase, which are the primary rate-limiting enzyme for
251 the synthesis of inborn long-chain PUFAs and is encoded by the fatty acid desaturase 1 (*FADS1*) gene

252 and fatty acid desaturase 2 (*FADS2*) gene (Simopoulos, 2010). Even the aortic valve's fatty acid
253 composition might be impacted by *FADS1* (Plunde et al., 2020). In our COLOC analysis, we
254 identified shared causal SNP of omega-3 fatty acid and IA, aSAH in gene fatty acid desaturase 2
255 (*FADS2*), respectively. The same result was also found in DHA, omega-3-pct, omega-6 by omega-3. It
256 is obvious that omega-3 fatty acids play a vital role in vascular-related diseases. Conversely, it's
257 incorrect to assume that all forms of omega-6 fatty acids would worsen blood vessel damage. More
258 thorough large-sample study is still required for additional validation.

259 However, several limitations should be taken into account in our study. First, given that the
260 participants in this study were from European population, the results of this study cannot be smoothly
261 extrapolated to other ethnic groups with diverse lifestyles and cultural backgrounds. Hence, further
262 multi-ancestry studies are needed to evaluate whether our findings can be generalized to individuals of
263 other ancestries. Second, since MR analyses extrapolated causal hypotheses by exploiting the random
264 allocation of genetic variants, it was difficult to completely distinguish between mediation and
265 pleiotropy using MR approaches. The generous variants in our genome probably affect one or more
266 phenotypes, even though we made an effort to remove the impacts of pleiotropic and heterogeneous
267 factors and confounders, some effects may still be there. Third, not all SNPs were examined, as some
268 were removed because of LD (and no proxy SNPs were found), which may have impacted the results.
269 Fourth PUFAs were measured from nonfasting peripheral plasma specimens, not aneurysm cavity
270 blood and aneurysm wall tissue Fifth, there is currently a lack of GWAS datasets of cerebral aneurysms
271 from different cerebrovascular sites, and exploring the relationship between genetically predicted
272 PUFAs and the occurrence of specific types of cerebral aneurysms remains a challenge in current MR
273 analyses.

274 **Conclusion**

275 In view of the extremely poor prognosis of cerebral aneurysms and the high mortality rate of
276 secondary rupture, our research focuses on the causal relationship between PUFAs and cerebral
277 aneurysms to improve our understanding of the pathogenic mechanism of various PUFAs in cerebral
278 aneurysms. And provide new insights into the diagnosis and treatment of brain aneurysms in the future.

279 **Acknowledgements**

280 The authors want to acknowledge all of the participants and investigators for contributing and sharing
281 summary-level data on GWAS.

282 **Consent for Publication**

283 All participants provided informed consent before enrollment in our study.

284 **Disclosures**

285 The authors declare that they have no competing interests.

286 **Author contributions**

287 Study design: Weijie Yu, Yunyun Mei, Liwei Zhou and Zhanxiang Wang. Acquisition of datasets:
288 Weijie Yu, Yunyun Mei, Chongfei Li, Xiaoyan Chen, Zhenwei Lu, Qionghui Huang and Zhangyu Li.

289 Data analysis: Weijie Yu, Yunyun Mei and Chongfei Li. Manuscript drafting: Weijie Yu and Yunyun
290 Mei. Manuscript revision: Liwei Zhou and Zhanxiang Wang. Final approval of manuscript: all authors.

291 **Ethical Approval**

292 Due to the fact that each of the original GWASs had obtained ethical approval and participant consent,
293 they were not required.

294 **Data availability**

295 The original contributions presented in the study are included in the article/supplementary material.
296 Further inquiries can be directed to the corresponding author.

297

298 **References**

- 299 Aoki T, Frösen J, Fukuda M, Bando K, Shioi G, Tsuji K, Ollikainen E, Nozaki K, Laakkonen J,
300 Narumiya S. 2017. Prostaglandin E2-EP2-NF- κ B signaling in macrophages as a potential therapeutic
301 target for intracranial aneurysms. *Science signaling*. 10465. DOI: 10.1126/scisignal.aah6037
- 302 Vlak MH, Algra A, Brandenburg R, Rinkel GJ. 2011. Prevalence of unruptured intracranial aneurysms,
303 with emphasis on sex, age, comorbidity, country, and time period: a systematic review and
304 meta-analysis. *The Lancet Neurology*. 107:626-636. DOI: 10.1016/s1474-4422(11)70109-0
- 305 Macdonald RL, Schweizer TA. 2017. Spontaneous subarachnoid haemorrhage. *The Lancet*.
- 306 Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, Bian Z, Pei P, Pan D, Zhang Y, Qin H,
307 Wang Y, Lv J, Liu M, Hao Z, Wang Y, Yu C, Peto R, Collins R, Li L, Clarke R, Chen Z. 2020.
308 Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of
309 0.5 million Chinese adults. *The Lancet Global health*. 84:e580-e590. DOI:
310 10.1016/s2214-109x(20)30069-3
- 311 Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. 2009. Changes in case fatality of
312 aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis.
313 *The Lancet Neurology*. 87:635-642. DOI: 10.1016/s1474-4422(09)70126-7
- 314 Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM.
315 1989. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and
316 reinfarction trial (DART). *Lancet (London, England)*. 28666:757-761. DOI:
317 10.1016/s0140-6736(89)90828-3
- 318 Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. 2006. n-3
319 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular
320 disease outcomes in primary- and secondary-prevention studies: a systematic review. *The American*
321 *journal of clinical nutrition*. 841:5-17. DOI: 10.1093/ajcn/84.1.5
- 322 Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, Weksler BB, De Caterina R.
323 2006. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction
324 through both NADP(H) oxidase and PKC epsilon inhibition. *Proceedings of the National Academy of*
325 *Sciences of the United States of America*. 10341:15184-15189. DOI: 10.1073/pnas.0510086103
- 326 Yang YC, Lii CK, Wei YL, Li CC, Lu CY, Liu KL, Chen HW. 2013. Docosahexaenoic acid inhibition
327 of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF- κ B pathways.

- 328 *The Journal of nutritional biochemistry*. 241:204-212. DOI: 10.1016/j.jnutbio.2012.05.003
- 329 Carrepeiro MM, Rogero MM, Bertolami MC, Botelho PB, Castro N, Castro IA. 2011. Effect of n-3
330 fatty acids and statins on oxidative stress in statin-treated hypercholesterolemic and
331 normocholesterolemic women. *Atherosclerosis*. 217:171-178. DOI:
332 10.1016/j.atherosclerosis.2010.12.013
- 333 Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaddous A, Bouchenak M. 2010. Effects of omega-3
334 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with
335 dyslipidemia. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the
336 National Kidney Foundation*. 205:321-328. DOI: 10.1053/j.jrn.2010.01.002
- 337 Calviello G, Serini S, Palozza P. 2006. n-3 polyunsaturated fatty acids as signal transduction
338 modulators and therapeutical agents in cancer. *Current Signal Transduction Therapy*. 13:255-271.
- 339 Meital LT, Windsor MT, Ramirez Jewell RML, Young P, Schulze K, Magee R, O'Donnell J, Jha P,
340 Perissiou M, Golledge J, Bailey TG, Brooks P, Askew CD, Russell FD. 2019. n-3 PUFAs improve
341 erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial. *Journal of lipid
342 research*. 60:1154-1163. DOI: 10.1194/jlr.P093013
- 343 Meital LT, Schulze K, Magee R, O'Donnell J, Jha P, Meital CY, Donkin R, Bailey TG, Askew CD,
344 Russell FD. 2020. Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in
345 Abdominal Aortic Aneurysm: A Randomized Controlled Trial. *Nutrients*. 13:1. DOI:
346 10.3390/nu13010138
- 347 Meital LT, Windsor MT, Perissiou M, Schulze K, Magee R, Kuballa A, Golledge J, Bailey TG, Askew
348 CD, Russell FD. 2019. Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages
349 from patients with small abdominal aortic aneurysm. *Scientific reports*. 9:12978. DOI:
350 10.1038/s41598-019-49362-z
- 351 Wang Y, Xie Y, Wang H, Zhang J, Li C, Chen F, Ren C, Xu Z, Liu M, Li L, Li T, Wang W. 2021.
352 Development and Clinical Translation of a Perioperative Nomogram Incorporating Free Fatty Acids to
353 Predict Poor Outcome of Aneurysmal Subarachnoid Hemorrhage Following Endovascular Treatment.
354 *Frontiers in neurology*. 12:629997. DOI: 10.3389/fneur.2021.629997
- 355 Takeda R, Islam A, Sato T, Kurita H, Kahyo T, Urano T, Setou M. 2021. The stability of the metabolic
356 turnover of arachidonic acid in human unruptured intracranial aneurysmal walls is sustained. *Clinical
357 neurology and neurosurgery*. 208:106881. DOI: 10.1016/j.clineuro.2021.106881
- 358 Davey Smith G, Hemani G. 2014. Mendelian randomization: genetic anchors for causal inference in
359 epidemiological studies. *Human molecular genetics*. 23R1:R89-98. DOI: 10.1093/hmg/ddu328
- 360 Hu C, Zhou Y, Wu X, Jia X, Zhu Y, Zheng R, Wang S, Lin L, Qi H, Lin H, Li M, Wang T, Zhao Z, Xu
361 M, Xu Y, Chen Y, Ning G, Borges MC, Wang W, Zheng J, Bi Y, Lu J. 2023. Evaluating the distinct
362 pleiotropic effects of omega-3 fatty acids on type 2 diabetes mellitus: a mendelian randomization study.
363 *Journal of translational medicine*. 21:370. DOI: 10.1186/s12967-023-04202-7
- 364 Yuan S, Bäck M, Bruzelius M, Mason AM, Burgess S, Larsson S. 2019. Plasma Phospholipid Fatty
365 Acids, FADS1 and Risk of 15 Cardiovascular Diseases: A Mendelian Randomisation Study. *Nutrients*.
366 11:112. DOI: 10.3390/nu11123001
- 367 Boef AG, Dekkers OM, le Cessie S. 2015. Mendelian randomization studies: a review of the
368 approaches used and the quality of reporting. *International journal of epidemiology*. 44:496-511. DOI:
369 10.1093/ije/dyv071
- 370 Borges MC, Haycock PC, Zheng J, Hemani G, Holmes MV, Davey Smith G, Hingorani AD, Lawlor
371 DA. 2022. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis

372 using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank
373 participants. *BMC medicine*. 201:210. DOI: 10.1186/s12916-022-02399-w

374 Julkunen H, Cichońska A, Slagboom PE, Würtz P. 2021. Metabolic biomarker profiling for
375 identification of susceptibility to severe pneumonia and COVID-19 in the general population. *eLife*. 10.
376 DOI: 10.7554/eLife.63033

377 Bakker MK, van der Spek RAA, van Rheenen W, Morel S, Bourcier R, Hostettler IC, Alg VS, van Eijk
378 KR, Koido M, Akiyama M, Terao C, Matsuda K, Walters RG, Lin K, Li L, Millwood IY, Chen Z,
379 Rouleau GA, Zhou S, Rannikmäe K, Sudlow CLM, Houlden H, van den Berg LH, Dina C, Naggara O,
380 Gentric JC, Shotar E, Eugène F, Desal H, Winsvold BS, Børte S, Johnsen MB, Brumpton BM, Sandvei
381 MS, Willer CJ, Hveem K, Zwart JA, Verschuren WMM, Friedrich CM, Hirsch S, Schilling S,
382 Dauvillier J, Martin O, Jones GT, Bown MJ, Ko NU, Kim H, Coleman JRI, Breen G, Zaroff JG, Klijn
383 CJM, Malik R, Dichgans M, Sargurupremraj M, Tatlisumak T, Amouyel P, Debette S, Rinkel GJE,
384 Worrall BB, Pera J, Slowik A, Gaál-Paavola EI, Niemelä M, Jääskeläinen JE, von Und Zu Fraunberg M,
385 Lindgren A, Broderick JP, Werring DJ, Woo D, Redon R, Bijlenga P, Kamatani Y, Veldink JH, Ruigrok
386 YM. 2020. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic
387 overlap with clinical risk factors. *Nature genetics*. 5212:1303-1313. DOI:
388 10.1038/s41588-020-00725-7

389 McDowell MM, Zhao Y, Kellner CP, Barton SM, Sussman E, Claassen J, Ducruet AF, Connolly ES.
390 2018. Demographic and clinical predictors of multiple intracranial aneurysms in patients with
391 subarachnoid hemorrhage. *Journal of neurosurgery*. 1284:961-968. DOI: 10.3171/2017.1.Jns162785

392 Sun X, Liu B, Chen Y, Lv L, Ye D, Mao Y. 2022. Modifiable risk factors for intracranial aneurysms:
393 Evidence from genetic studies. *International journal of stroke : official journal of the International
394 Stroke Society*. 1710:1107-1113. DOI: 10.1177/17474930211065640

395 Tian D, Zhang L, Zhuang Z, Huang T, Fan D. 2022. A two-sample Mendelian randomization analysis
396 of modifiable risk factors and intracranial aneurysms. *Scientific reports*. 121:7659. DOI:
397 10.1038/s41598-022-11720-9

398 Huang Q, Shang-Guan HC, Wu SY, Yao PS, Sun Y, Zeng YL, Zheng SF, Chen GR, Lin YX, Kang DZ.
399 2018. High-Density Lipoprotein Is Associated with Progression of Intracranial Aneurysms. *World
400 neurosurgery*. 120:e234-e240. DOI: 10.1016/j.wneu.2018.08.037

401 Bowden J, Davey Smith G, Burgess S. 2015. Mendelian randomization with invalid instruments: effect
402 estimation and bias detection through Egger regression. *International journal of epidemiology*.
403 442:512-525. DOI: 10.1093/ije/dyv080

404 Bowden J, Davey Smith G, Haycock PC, Burgess S. 2016. Consistent Estimation in Mendelian
405 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic
406 epidemiology*. 404:304-314. DOI: 10.1002/gepi.21965

407 Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H,
408 Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto
409 AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rieger S, Lemmelä S, Zhou W,
410 Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J,
411 Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas
412 S, Bizaki-Vallaskangas A, Carpen O, Chen CY, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M,
413 Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman Å K,
414 Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H,
415 Jensen JN, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R,

416 Kallio L, Kälviäinen R, Kaprio J, Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma
417 VM, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longereich S, Mägi R, Mäkelä J,
418 Mäkitie A, Malarstig A, Mannermaa A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi
419 MEK, Niemi M, Niiranen T, CJ OD, Obeidat ME, Okafo G, Ollila HM, Palomäki A, Palotie T,
420 Partanen J, Paul DS, Pelkonen M, Pendergrass RK, Petrovski S, Pitkäranta A, Platt A, Pulford D,
421 Punkka E, Pussinen P, Raghavan N, Rahimov F, Rajpal D, Renaud NA, Riley-Gillis B, Rodosthenous
422 R, Saarentaus E, Salminen A, Salminen E, Salomaa V, Schleutker J, Serpi R, Shen HY, Siegel R,
423 Silander K, Siltanen S, Soini S, Soininen H, Sul JH, Tachmazidou I, Tasanen K, Tienari P,
424 Toppila-Salmi S, Tukiainen T, Tuomi T, Turunen JA, Ulirsch JC, Vaura F, Virolainen P, Waring J,
425 Waterworth D, Yang R, Nelis M, Reigo A, Metspalu A, Milani L, Esko T, Fox C, Havulinna AS, Perola
426 M, Ripatti S, Jalanko A, Laitinen T, Mäkelä TP, Plenge R, McCarthy M, Runz H, Daly MJ, Palotie A.
427 2023. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature*.
428 6137944:508-518. DOI: 10.1038/s41586-022-05473-8
429 Pierce BL, Ahsan H, Vanderweele TJ. 2011. Power and instrument strength requirements for Mendelian
430 randomization studies using multiple genetic variants. *International journal of epidemiology*.
431 403:740-752. DOI: 10.1093/ije/dyq151
432 Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, Chatterjee N. 2010. Estimation of
433 effect size distribution from genome-wide association studies and implications for future discoveries.
434 *Nature genetics*. 427:570-575. DOI: 10.1038/ng.610
435 Ge P, Liu C, Chan L, Pang Y, Li H, Zhang Q, Ye X, Wang J, Wang R, Zhang Y, Wang W, Zhang D,
436 Zhao J. 2022. High-Dimensional Immune Profiling by Mass Cytometry Revealed the Circulating
437 Immune Cell Landscape in Patients With Intracranial Aneurysm. *Frontiers in immunology*. 13:922000.
438 DOI: 10.3389/fimmu.2022.922000
439 Nakatomi H, Segawa H, Kurata A, Shiokawa Y, Nagata K, Kamiyama H, Ueki K, Kirino T. 2000.
440 Clinicopathological study of intracranial fusiform and dolichoectatic aneurysms : insight on the
441 mechanism of growth. *Stroke*. 314:896-900. DOI: 10.1161/01.str.31.4.896
442 Meng H, Tutino VM, Xiang J, Siddiqui A. 2014. High WSS or low WSS? Complex interactions of
443 hemodynamics with intracranial aneurysm initiation, growth, and rupture: toward a unifying hypothesis.
444 *AJNR American journal of neuroradiology*. 357:1254-1262. DOI: 10.3174/ajnr.A3558
445 Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT,
446 Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K,
447 Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plataras J, Roberts LJ, 2nd, Rokach J, Shigenaga
448 MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC.
449 2005. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA
450 markers of CCl4 poisoning? *Free radical biology & medicine*. 386:698-710. DOI:
451 10.1016/j.freeradbiomed.2004.09.017
452 Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD, Hasty AH. 2007. Fish oil increases
453 cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic
454 steatosis, and atherosclerosis in mice. *The Journal of nutrition*. 1377:1776-1782. DOI:
455 10.1093/jn/137.7.1776
456 Zúñiga J, Venegas F, Villarreal M, Núñez D, Chandía M, Valenzuela R, Tapia G, Varela P, Videla LA,
457 Fernández V. 2010. Protection against in vivo liver ischemia-reperfusion injury by n-3 long-chain
458 polyunsaturated fatty acids in the rat. *Free radical research*. 448:854-863. DOI:
459 10.3109/10715762.2010.485995

460 Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. 2003. Effect of eicosapentaenoic
461 acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive
462 type 2 diabetic subjects. *Free radical biology & medicine*. 357:772-781. DOI:
463 10.1016/s0891-5849(03)00407-6

464 Barden AE, Burke V, Mas E, Beilin LJ, Puddey IB, Watts GF, Irish AB, Mori TA. 2015. n-3 fatty acids
465 reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney
466 disease. *Journal of hypertension*. 339:1947-1953. DOI: 10.1097/hjh.0000000000000621

467 Nakagawa I, Yokoyama S, Omoto K, Takeshima Y, Matsuda R, Nishimura F, Yamada S, Yokota H,
468 Motoyama Y, Park YS, Nakase H. 2017. ω -3 Fatty Acids Ethyl Esters Suppress Cerebral Vasospasm
469 and Improve Clinical Outcome Following Aneurysmal Subarachnoid Hemorrhage. *World neurosurgery*.
470 99:457-464. DOI: 10.1016/j.wneu.2016.12.018

471 Saito G, Zapata R, Rivera R, Zambrano H, Rojas D, Acevedo H, Ravera F, Mosquera J, Vásquez JE,
472 Mura J. 2017. Long-chain omega-3 fatty acids in aneurysmal subarachnoid hemorrhage: A randomized
473 pilot trial of pharmaconutrition. *Surgical neurology international*. 8:304. DOI: 10.4103/sni.sni_266_17

474 Gewirtz RJ, Dhillon HS, Goes SE, DeAtley SM, Scheff SW. 1999. Lactate and free fatty acids after
475 subarachnoid hemorrhage. *Brain research*. 8401-2:84-91. DOI: 10.1016/s0006-8993(99)01752-7

476 Ikedo T, Minami M, Kataoka H, Hayashi K, Nagata M, Fujikawa R, Yamazaki F, Setou M, Yokode M,
477 Miyamoto S. 2018. Imaging mass spectroscopy delineates the thinned and thickened walls of
478 intracranial aneurysms. *Biochemical and biophysical research communications*. 4951:332-338. DOI:
479 10.1016/j.bbrc.2017.10.133

480 Simopoulos AP. 2010. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their
481 role in the determination of nutritional requirements and chronic disease risk. *Experimental biology
482 and medicine (Maywood, NJ)*. 2357:785-795. DOI: 10.1258/ebm.2010.009298

483 Plunde O, Larsson SC, Artiach G, Thanassoulis G, Carracedo M, Franco-Cereceda A, Eriksson P, Bäck
484 M. 2020. FADS1 (Fatty Acid Desaturase 1) Genotype Associates With Aortic Valve FADS mRNA
485 Expression, Fatty Acid Content and Calcification. *Circulation Genomic and precision medicine*.
486 133:e002710. DOI: 10.1161/circgen.119.002710

487

488

489 **Figure legends**

490 Figure 1. Flowchart showing Mendelian randomization.

491 MR, Mendelian randomization; MR-PRESSO, Mendelian randomization pleiotropy residual sum and
492 outlier; SNPs, single-nucleotide polymorphisms; MVMR, multivariable Mendelian randomization;
493 IVW, inverse variance weighting; PUFA: polyunsaturated fatty acids; COLOC: colocalization.

494

495 Figure 2. Mendelian randomization analysis of the association between PUFA and IA.

496 PUFA: polyunsaturated fatty acids; IA: intracranial aneurysm; nSNP: number of single-nucleotide
497 polymorphisms; OR: odds ratio; CI: confidence interval; MR, Mendelian randomization; IVW, inverse
498 variance weighting; DHA: docosahexaenoic acid.

499

500 Figure 3. Mendelian randomization analysis of the association between PUFA and aSAH.


501 PUFA: polyunsaturated fatty acids; aSAH: aneurysmal subarachnoid hemorrhage; nSNP: number of
502 single-nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; MR, Mendelian
503 randomization; IVW, inverse variance weighting; DHA: docosahexaenoic acid.

504

505 Figure 4. Mendelian randomization analysis of the association between PUFA and uIA.


506 PUFA: polyunsaturated fatty acids; uIA: unruptured intracranial aneurysm; nSNP: number of
507 single-nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; MR, Mendelian
508 randomization; IVW, inverse variance weighting; DHA: docosahexaenoic acid.

509




Outcome	Exposure	Method	nSNP	OR(95%CI)		p-value
IA	Omega-3	IVW	15	0.80(0.69 to 0.91)		1.01E-03
	DHA		11	0.75(0.63 to 0.87)		3.12E-04
	Omega-3-pct		8	0.80(0.71 to 0.90)		2.34E-04
	Omega-6 by Omega-3		12	1.27(1.12 to 1.44)		1.53E-04
	Omega-6		19	0.78(0.57 to 1.06)		1.13E-01

p<0.0033 was considered statistically significant



Outcome	Exposure	Method	nSNP	OR(95%CI)		p-value
aSAH	Omega-3	IVW	13	0.71(0.61 to 0.84)		3.73E-05
	DHA		9	0.67(0.55 to 0.80)		2.32E-05
	Omega-3-pct		7	0.76(0.66 to 0.87)		1.16E-04
	Omega-6 by Omega-3		11	1.35(1.17 to 1.56)		5.78E-05
	Omega-6		19	0.82(0.62 to 1.08)		1.53E-01

p<0.0033 was considered statistically significant



Outcome	Exposure	Method	nSNP	OR(95%CI)	p-value
uIA	Omega-3	IVW	26	0.91(0.76 to 1.08)	2.71E-01
	DHA		21	0.93(0.76 to 1.14)	4.79E-01
	Omega-3-pct		18	0.97(0.82 to 1.13)	6.65E-01
	Omega-6 by Omega-3		19	1.01(0.90 to 1.25)	4.82E-01
	Omega-6		27	0.87(0.62 to 1.24)	4.43E-01

p < 0.0033 was considered statistically significant

